Associate Professor, Internal Medicine, Ohio State University College of Medicine; Clinical Director, Blood and Marrow Transplant Program
Hematology
Dr. Leslie A. Andritsos, MD
|
|
Give Review
Leslie Andritsos works in the field of Hematology. He received 2 awards: "Alpha Omega Alpha" and "CMS Meaningful Use Stage 1 Certification". Leslie Andritsos is a published doctor as well. He has 57 publications published. The latest was: Ibrutinib for treatment of chronic lymphocytic leukemia. Dr. Leslie A. Andritsos is registered with Medicare and accepts Medicare payments.
Publications
- Ibrutinib for treatment of chronic lymphocytic Leukemia.
- Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic Leukemia.
- Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic Leukemia patients.
- Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT).
- Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic Leukemia (CLL).
- Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic Leukemia and small lymphocytic lymphoma.
- Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic Leukemia.
- Dinaciclib is a novel cyclin dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic Leukemia.
- Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic Leukemia.
- Cotreatment of hairy cell Leukemia and melanoma with the BRAF inhibitor dabrafenib.
- Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma.
- Lower dose of antithymocyte globulin does not increase graft-versus-host Disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem ce...
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk Lymphoma.
- Reduced dose pentostatin for initial management of hairy cell Leukemia patients who have active infection or risk of hemorrhage is safe and effective.
- The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for Lymphoma and multiple myeloma.
- OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic Leukemia cells.
- A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic Leukemia.
- Hairy cell Leukemia: Update on molecular profiling and therapeutic advances.
- Mitochondrial priming of chronic lymphocytic Leukemia patients associates Bcl-xL dependence with alvocidib response.
- PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates pre-clinical activity in CLL.
- Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic Leukemia.
- An effective mobilization strategy for Lymphoma patients after failed upfront mobilization with plerixafor.
- Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem Cell transplants in patie...
- Multifocal epithelial hyperplasia (Heck disease) in a patient with chronic lymphocytic Leukemia.
- Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic Leukemia cells.
- The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine Leukemia model.
- Impact of targeted therapy on outcome of chronic lymphocytic Leukemia patients with relapsed del(17p13.1) karyotype at a single center.
- A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab (TRU-016), an Anti-CD37 Mono-specific ADAPTIRTM Therapeutic Protein in Chronic Lymphocytic Leuke...
- Lymphocyte cytosolic protein 1 is a chronic lymphocytic Leukemia membrane-associated antigen critical to niche homing.
- Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory Non-Hodgkin's Lymphoma.
- Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic Leukemia.
- Outcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study.
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes.
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and Acute B cell malignancies.
- Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell Lymphoma.
- Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia.
- Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-Cell transplantation.
- Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for Chronic lymphocytic leukaemia.
- ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
- Phase II study of flavopiridol in relapsed chronic lymphocytic Leukemia demonstrating high response rates in genetically high-risk disease.
- Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic Leukemia.
- Molecular markers of clonality and identity in Epstein-Barr virus-associated B-cell lymphoproliferative Disease.
- Characterization of a new chronic lymphocytic Leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease.
- Dic(17;18)(p11.2;p11.2) is a recurring abnormality in Chronic lymphocytic leukaemia associated with aggressive disease.
- Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events an...
- Salvage therapy for relapsed chronic lymphocytic Leukemia.
- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic Leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
- Enhanced detection of chromosomal abnormalities in chronic lymphocytic Leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mit...
- Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic Cell transplantation following fludarabine, busulfan-based re...
- Phosphatidylinositol 3-kinase-? inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic Leukemia by antagonizing intrinsic and extrinsic cellular...
- Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin Lymphoma: dose-limiting myelosuppres...
- Second malignancies in B-cell Chronic lymphocytic leukaemia: possible association with human papilloma virus.
- Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic Leukemia.
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplanta...
- Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic Leukemia c...
- Lenalidomide treatment promotes CD154 expression on CLL Cells and enhances production of antibodies by normal B Cells through a PI3-kinase-dependent pathway.
Schools
University Of Texas Medical Branch At Galveston
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Frontpath Health Coalition
- Golden Rule
- Humana
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- Molina
- Mutual of Omaha
- Priority Health
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Wells Fargo Insurance
Awards
- Alpha Omega Alpha
- CMS Meaningful Use Stage 1 Certification
Education
-
Washington University -
Washington University - Barnes-Jewish Hospital -
University of Texas Medical Branch
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1316919418 | |
| NPPES Provider LastName | ANDRITSOS | |
| NPPES Provider FirstName | LESLIE | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology | |
| Total Claim Count | 179.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316919418 |
| Last Name Of The Provider | ANDRITSOS |
| First Name Of The Provider | LESLIE |
| View All |
Similar Doctors
|
Dr. Clara D. Bloomfield, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Mark S. Collins, MD |
|
|
Dr. Kami J. Maddocks-Christianson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Robert A. Baiocchi, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Mark L. Segal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark D. Brownell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Don M. Benson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael R. Grever, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Payal C. Desai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter G. Shields, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew V. Grainger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Monroe D. Dowling Jr., MD
This Doctor is OpenDoctor Recommended.
|